Tags

Type your tag names separated by a space and hit enter

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.
Intern Med J. 2007 Feb; 37(2):79-86.IM

Abstract

BACKGROUND

Metformin is considered the gold standard for type 2 diabetes treatment as monotherapy and in combination with sulphonylureas and insulin, whereas the combination of metformin with thiazolidinediones is relatively less studied. The aim of the present study was to assess the differential effect on glycaemic metabolism and lipid variables of the combination of metformin plus pioglitazone or metformin plus rosiglitazone in diabetic patients with metabolic syndrome.

METHODS

All patients began metformin and were randomized to receive pioglitazone or rosiglitazone for 12 months. We assessed body mass index, glycated haemoglobin, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin, postprandial plasma insulin, homeostasis model assessment index, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B.

RESULTS

Significant decreases in glycated haemoglobin, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin, and postprandial plasma insulin were seen after 9 and 12 months in both groups. Homeostasis model assessment index improved at 12 months in both groups. Significant total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B improvement was observed in pioglitazone group after 12 months, but not in the rosiglitazone group. These variations were significant between groups.

CONCLUSION

The combination of metformin plus thiazolidinediones was able to improve glycaemic control compared with previous therapy. Pioglitazone was associated with a significant improvement in lipid and lipoprotein variables.

Authors+Show Affiliations

Department of Internal Medicine and Therapeutics, University of Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy. giuseppe.derosa@unipv.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

17229249

Citation

Derosa, G, et al. "Metabolic Effects of Pioglitazone and Rosiglitazone in Patients With Diabetes and Metabolic Syndrome Treated With Metformin." Internal Medicine Journal, vol. 37, no. 2, 2007, pp. 79-86.
Derosa G, D'Angelo A, Ragonesi PD, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J. 2007;37(2):79-86.
Derosa, G., D'Angelo, A., Ragonesi, P. D., Ciccarelli, L., Piccinni, M. N., Pricolo, F., Salvadeo, S. A., Montagna, L., Gravina, A., Ferrari, I., Paniga, S., & Cicero, A. F. (2007). Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Internal Medicine Journal, 37(2), 79-86.
Derosa G, et al. Metabolic Effects of Pioglitazone and Rosiglitazone in Patients With Diabetes and Metabolic Syndrome Treated With Metformin. Intern Med J. 2007;37(2):79-86. PubMed PMID: 17229249.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. AU - Derosa,G, AU - D'Angelo,A, AU - Ragonesi,P D, AU - Ciccarelli,L, AU - Piccinni,M N, AU - Pricolo,F, AU - Salvadeo,S A T, AU - Montagna,L, AU - Gravina,A, AU - Ferrari,I, AU - Paniga,S, AU - Cicero,A F G, PY - 2007/1/19/pubmed PY - 2007/3/23/medline PY - 2007/1/19/entrez SP - 79 EP - 86 JF - Internal medicine journal JO - Intern Med J VL - 37 IS - 2 N2 - BACKGROUND: Metformin is considered the gold standard for type 2 diabetes treatment as monotherapy and in combination with sulphonylureas and insulin, whereas the combination of metformin with thiazolidinediones is relatively less studied. The aim of the present study was to assess the differential effect on glycaemic metabolism and lipid variables of the combination of metformin plus pioglitazone or metformin plus rosiglitazone in diabetic patients with metabolic syndrome. METHODS: All patients began metformin and were randomized to receive pioglitazone or rosiglitazone for 12 months. We assessed body mass index, glycated haemoglobin, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin, postprandial plasma insulin, homeostasis model assessment index, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B. RESULTS: Significant decreases in glycated haemoglobin, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin, and postprandial plasma insulin were seen after 9 and 12 months in both groups. Homeostasis model assessment index improved at 12 months in both groups. Significant total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B improvement was observed in pioglitazone group after 12 months, but not in the rosiglitazone group. These variations were significant between groups. CONCLUSION: The combination of metformin plus thiazolidinediones was able to improve glycaemic control compared with previous therapy. Pioglitazone was associated with a significant improvement in lipid and lipoprotein variables. SN - 1445-5994 UR - https://www.unboundmedicine.com/medline/citation/17229249/Metabolic_effects_of_pioglitazone_and_rosiglitazone_in_patients_with_diabetes_and_metabolic_syndrome_treated_with_metformin_ L2 - https://doi.org/10.1111/j.1445-5994.2007.01238.x DB - PRIME DP - Unbound Medicine ER -